Nimble Therapeutics is at the forefront of developing oral peptide therapies aimed at treating immune-mediated diseases. The company utilizes a proprietary light-directed peptide synthesis platform that can generate over 100 million unique peptidomimetic compounds in a single night. This platform is designed to optimize oral peptide therapeutics by enabling rapid screening and a deeper understanding of molecular interactions, which are crucial for enhancing parameters such as potency, stability, and bioavailability. Nimble's approach emphasizes the importance of addressing significant unmet patient needs through innovative oral treatments that can improve clinical outcomes and patient convenience.

The company’s drug discovery capabilities are further enhanced by its advanced informatics and assay systems, which facilitate the characterization and optimization of peptide libraries. Nimble employs a comprehensive suite of biological assays to evaluate the binding, stability, and solubility of each peptide, allowing for data-driven discoveries that guide the selection of optimal leads for preclinical development. By integrating machine learning and computational methods with its synthesis and assay technologies, Nimble is positioned to rapidly iterate and refine its peptide candidates, ultimately aiming to deliver next-generation oral therapies that can significantly impact patient care.

United States

Nimble Therapeutics is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble is advancing its internal pipeline and continues to support several partnered programs. The Nimble platform combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful machine learning and computational methods.

Nimble Therapeutics

Company Details